Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling

Metastatic melanoma remains an incurable disease for many patients due to the limited success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic burden for patients with melanomas harboring BRAF mutations; however, most eventually relapse due to acquired resistance. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathi, Rakshamani, Liu, Zulong, Jain, Aditi, Lyon, Anastasia, Meeks, Christina, Richards, Dana, Liu, Jinpeng, He, Daheng, Wang, Chi, Nespi, Marika, Rymar, Andrey, Wang, Peng, Wilson, Melissa, Plattner, Rina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596241/
https://www.ncbi.nlm.nih.gov/pubmed/33122628
http://dx.doi.org/10.1038/s41467-020-19075-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596241/
https://www.ncbi.nlm.nih.gov/pubmed/33122628
http://dx.doi.org/10.1038/s41467-020-19075-3

Ejemplares similares